Aarti Drugs Limited
Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate, Ground Floor, Plot No. 109-D, Road No. 29, Sion (East), Mumbai - 400 022. (India)
Tel .: 022-2407 2249 / 2401 9025 (30 Lines)
Fax.: 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.:L37060MH1984PLC055433

Ref: ADL/SE/2025-26/53
November 7, 2025

To,
Listing/ Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001
BSE CODE: 524348

To,
Listing/ Compliance Department
National Stock Exchange of India Limited,
“Exchange Plaza”, Plot No. C/1,
G Block Bandra - Kurla Complex,
Bandra (East), Mumbai – 400051
NSE SYMBOL: AARTIDRUGS

Dear Sir/Madam,

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Sub: Press Release on Financial Results.

Please find attached herewith press release on Financial Results for the quarter and half year ended September 30, 2025.

Kindly take the same on record.

Thanking you,

Yours faithfully,
FOR AARTI DRUGS LIMITED

RUSHIKESH VIVEK DEOLE

RUSHIKESH DEOLE
COMPANY SECRETARY & COMPLIANCE OFFICER
ICSI M. No.: F12932

Aarti Drugs Ltd.

Q2 & H1 FY26 Business & Financial Performance

Mumbai, 7th November 2025

Aarti Drugs Limited (Aarti Drugs) (NSE: AARTIDRUGS; BSE:524348), a Mumbai based diversified and fully integrated pharmaceutical company, with interests in Active Pharmaceutical Ingredients (API), Formulation, Specialty Chemicals and Intermediates announced its unaudited financial results for the quarter and half year ended 30th September 2025.

Consolidated Financial Highlights

Particulars (In Rs. Crores)	Q2 FY26	Q2 FY25	YoY%	Q1 FY26	QoQ%	H1 FY26	H1 FY25	YoY%
Revenue	**652.9**	**599.8**	**9%**	**590.8**	**11%**	**1,243.7**	**1,156.3**	**8%**
Gross Profit#	244.6	205.8	19%	217.4	12%	462.0	402.4	15%
EBITDA*	**84.4**	**68.5**	**23%**	**74.4**	**13%**	**158.8**	**134.6**	**18%**
EBITDA Margin %	**12.9%**	**11.4%**	***150 bps***	**12.6%**	***30 bps***	**12.8%**	**11.6%**	***120 bps***
Profit Before Tax (PBT)	60.4	45.9	32%	51.1	18%	111.5	89.9	24%
Profit After Tax (PAT)	**45.2**	**35.0**	**29%**	**54.0**	**-16%**	**99.1**	**68.3**	**45%**
PAT Margin %	**6.9%**	**5.8%**	***110 bps***	**9.1%**	***-220 bps***	**8.0%**	**5.9%**	***210 bps***
EPS (in Rs.)	4.95	3.83		5.91		10.86	7.48	

Gross Profit = Revenue - Raw Material Consumed; *EBITDA excludes exceptional items but includes other income

Consolidated Financial Highlights – Q2 FY26

- **Revenue** stood at Rs. 652.9 crore as compared to Rs. 599.8 crore in Q2 FY25, reflecting a growth of 9% YoY, driven by favourable export volumes
- **EBITDA** stood at Rs. 84.4 crore versus Rs. 68.5 crore in Q2 FY25, up 23% YoY, with **EBITDA margin** at 12.9% versus 11.4% in Q2 FY25, an expansion of 150 basis points
- **PAT** stood at Rs. 45.2 crore as compared to Rs. 35.0 crore in Q2 FY25, up 29% YoY, translating to **a PAT margin** of 6.9% versus 5.8% last year, an improvement of 110 basis points

Consolidated Financial Highlights – H1 FY26

- **Revenue** stood at Rs. 1,243.7 crore as compared to Rs. 1,156.3 crore in H1 FY25, reflecting a growth of 8% YoY
- **EBITDA** stood at Rs. 158.8 crore versus Rs. 134.6 crore in H1 FY25, up 18% YoY, with **EBITDA margin** at 12.8% versus 11.6% in H1 FY25, an expansion of 120 basis points
- **PAT** stood at Rs. 99.1 crore as compared to Rs. 68.3 crore in Q2 FY25, up 45% YoY, translating to **a PAT margin** of 8.0% versus 5.9% last year, an improvement of 210 basis points

Segmental Performance Update

Particulars (In Rs. Crores)	Q2 FY26	Q2 FY25	YoY%	Q1 FY26	QoQ%	H1 FY26	H1 FY25	YoY%
API	**515.9**	482.6	7%	458.2	13%	**974.1**	925.3	5%
Formulations	**82.4**	65.6	26%	80.3	3%	**162.8**	136.1	20%
Specialty Chemicals	**37.3**	28.8	30%	33.1	13%	**70.4**	55.4	27%
Intermediates & Others	**17.1**	21.3	-20%	18.9	-10%	**36.1**	36.8	-2%

Aarti Drugs Ltd.

Standalone Business Highlights – Q2 FY26

- Revenue stood at Rs. 578.9 crores vs. Rs. 543.1 crores in Q2 FY25, growth by 7% YoY
- Standalone business contributed 89% to the consolidated revenue
- 58% of the standalone revenue came from the domestic market and 42% from the exports market
- Domestic revenue was down 7% YoY and export revenue increased by 33% YoY
- Within the API business, the anti-biotic therapeutic category contributed 36.1%, anti-diabetic 15.3%, anti-protozoal 18.8%, anti-inflammatory 11.8%, antifungal 11.7% and the rest contributed 6.4% to total API sales

Formulation Segment Highlights

- Revenue from formulations stood at Rs. 82.4 crore in Q2 FY26, compared to Rs. 65.6 crore in Q2 FY25, up 26% YoY. Exports contributed 68% to this revenue
- For H1 FY26, formulation revenue was Rs. 162.8 crore compared to Rs. 136.6 crore in H1 FY25, up 19%, with exports accounting for 63% of total formulation sales

Commenting on the same, Mr. Adhish Patil, CFO & COO, Aarti Drugs Limited said,

"*We are pleased with the operational progress achieved during the quarter.* Aarti Drugs posted revenue of Rs. *652.9 crore in Q2 FY26, growing 9% year-on-year, with EBITDA of Rs. 84.4 crore, up 23%, with margin at 12.9%. For H1 FY26, revenue was Rs. 1,243.7 crore, up 8% year-on-year, with EBITDA of Rs. 158.8 crore, up 18% with margin at 12.8%. The capex incurred during Q2 FY26 was Rs. ~45.6 crore.* Overall, our Q2 results reflect the benefit of favorable export mix and disciplined execution.

Q2 FY26 marked continued progress on our strategic priorities of backward integration, capacity expansion, and strengthening cost competitiveness, even as the broader industry witnessed soft domestic demand trends—particularly in the antibiotics category. Export demand, however, remained robust, offsetting the weakness in the domestic market and contributing to improvement in our overall margins.

The commissioning of our Sayakha amines facility in September 2025 marks a pivotal step in backward integration, enhancing raw material security and margin resilience. Around 40–50% of captive requirements of Metformin are now being met internally from this plant and is expected to scale up to fullfill the entire captive demand over the next 6-12 months.

Our salicylic acid operations at Tarapur are stabilizing well with near-term output of around 300 tonnes per month and targeting 500 tonnes per month for Q4 FY26. This vertical will feed another 400 tonnes per month salicylates line, delivering downstream integration, better overhead absorption and improved margin stability. These capacity additions aim to convert import dependence into domestic supply, and with the downstream salicylates line under implementation, this segment will become a key value driver in the coming years.

Aarti Drugs also continues to deepen its global presence with several EU and USFDA certifications obtained and some under-implementation for key products from large-scale plants. These approvals will enable export of higher-value APIs and formulations to regulated markets and from our lower-cost facilities.

With operating cash flows strengthening and capex largely behind us, the focus now shifts toward scaling utilization and converting our new assets into steady earnings contributors. Over FY27–FY29, we expect the combined contribution to drive sustainable margin expansion and value creation."

Aarti Drugs Ltd.

About Aarti Drugs Limited

Aarti Drugs Limited was established in the year 1984 and forms part of $6 Billion Aarti Group of Industries with robust R&D Division at Tarapur, Maharashtra Industrial Development Corporation (MIDC) in close vicinity to manufacturing locations. The Company is engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs), Pharma Intermediates, Speciality Chemicals and produces Formulations with its wholly-owned subsidiary-Pinnacle Life Science Private Limited. The Company have total 14 manufacturing facilities out of which 10 manufacturing facilities are in Maharashtra, 3 Manufacturing facilities in Gujarat and 1 Manufacturing facility of Pinnacle is located at Himachal Pradesh. Products under APIs include Ciprofloxacin Hydrochloride, Metronidazole, Metformin HCL, Ketoconazole, Ofloxacin etc. whereas Specialty Chemicals includes Benzene Sulphonyl Chloride, Methyl Nicotinate etc.

For more information, please visit www.aartidrugs.co.in

For more information, please contact

Company:	Investor Relations (IR)
Aarti Drugs Limited	**Strategic Growth Advisors Pvt. Ltd.**
Aarti Drugs Ltd.	SGA Strategic Growth Advisors
CIN: L37060MH1984PLC055433	CIN: U74140MH2010PTC204285
Mr. Rushikesh Deole	**Mr. Deven Dhruva / Ms. Krisha Shrimankar**
investorrelations@aartidrugs.com	deven.dhruva@sgapl.net / krisha.shrimankar@sgapl.net
+91 22 24048199	+91 98333 73300 / +91 87797 99281
www.aartidrugs.co.in	www.sgapl.net